Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration o…
The bill authorizes the President to negotiate and enter into “trusted trade partner” agreements that reciprocally reduce or eliminate duties and import restrictions on medical goods to strengthen U.S. medical supply chain resilience.
It specifies criteria for selecting partners (rule of law, IP protection, commitment to open trade in emergencies) and permits provisions on regulatory harmonization, procurement access, and IP protection.
The bill requires advance notice to Congress, periodic reports, consultation with committees and agencies, a timed congressional review and disapproval mechanism, and monitoring and enforcement authority for the Trade Representative and President.
Technocratic and limited scope help, but trade/IP/procurement implications and need for bipartisan consensus on negotiation authority create moderate barriers.
Relative to its intended legislative type, this bill establishes a substantive new authority for the executive branch to negotiate and implement trade agreements focused on medical goods and provides a detailed procedural framework (partner criteria, consultation, reporting, congressional review, and enforcement mechanisms).
Progressive worries IP protections will limit generic access
Progressive worries IP protections will limit generic access
Generally supportive of measures to diversify and secure medical supply chains but wary of strong IP and market-access provisions.
Sees benefits for pandemic preparedness and regulatory cooperation, but concerned that broad IP protections and duty eliminations could limit affordable generic access and domestic production.
Would favor added safeguards for public health access, labor, and environmental standards.
Pragmatic approval of a framework that improves preparedness while keeping congressional oversight and executive flexibility.
Values the bill's reporting, consultation, and disapproval mechanisms that provide checks on presidential negotiations.
Sees trade-based tools as efficient complements to domestic capacity-building, but seeks clear metrics and evidence requirements.
Cautious to skeptical: supports strengthening supply chains and strong IP protections, but worries about ceding tariff tools and expanding federal commitments.
Concerned agreements might constrain emergency powers, disadvantage U.S. manufacturers, or increase regulatory entanglement.
Prefers narrow agreements with strong national-security safeguards and preservation of sovereign emergency authorities.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technocratic and limited scope help, but trade/IP/procurement implications and need for bipartisan consensus on negotiation authority create moderate barriers.
The bill has not accumulated any surfaced votes yet.
Progressive worries IP protections will limit generic access
Technocratic and limited scope help, but trade/IP/procurement implications and need for bipartisan consensus on negotiation authority creat…
Relative to its intended legislative type, this bill establishes a substantive new authority for the executive branch to negotiate and implement trade agreements focused on medical goods and provides a detailed procedur…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.